CGM in Perimenopause: Glucose Variability Across the Transition

Not a diagnosis. A description, of four things in particular.

Larger post-meal rises. The same breakfast that produced a modest rise a decade ago produces a taller, longer one. This is the insulin-resistance shift made visible, and it is often the first thing a woman notices on the trace.

A higher, flatter overnight line. The liver's overnight glucose release, less restrained by estrogen and by insulin, shows as a fasting glucose that has crept up — the number the vs-A1c page explains a single morning draw may or may not catch.

The sleep-glucose loop. A night broken by hot flushes or by the insomnia of the transition shows the next day as higher glucose and larger post-meal rises, because a poor night raises cortisol and lowers insulin sensitivity. The following night is then worse, because higher glucose and its hormonal echo fragment sleep further. On a sensor the loop is visible in a way no single lab can show: the bad nights and the bad days line up. It is one of the most useful things the trace teaches, because it tells the woman — and the clinician — that the sleep is the lever.

Cycle-tracked variation. For a woman still cycling, the trace changes with the cycle: glucose handling is typically better in the first half and worse in the second, and in perimenopause, with cycles irregular and hormone levels swinging, the pattern becomes noisier. It is a reason the two-week run may not represent the month, and a reason the interpretation needs the dates.

Whether she is in perimenopause — that is a clinical diagnosis from symptoms and, where useful, the hormone panel. Whether she has prediabetes — that is an A1c and fasting glucose, which the trace complements and does not replace. And whether hormone therapy would help her glucose — that is a decision made on symptoms and the HRT evidence, with the metabolic benefit as a secondary consideration rather than the reason.

The main page is honest that the outcome evidence for CGM in people without diabetes is thin, and that the benefit in the studies was confined to people with prediabetes. A perimenopausal woman is the population that argument most favors: her risk of crossing into prediabetes is rising, the sensor shows the crossing in progress, and the things that reverse it — sleep, strength training, the walk after a meal on the exercise page, and where indicated the treatments above — are within reach.

When the trace, read alongside the panel, shows a woman whose glucose handling has shifted into the range where metformin has evidence — the decision is on that page. When it shows that broken sleep is driving the daytime pattern — the decision is to treat the sleep, which in perimenopause is often the hormone therapy conversation. When it shows a normal trace in a woman who feared otherwise — the decision is reassurance, and that is a real outcome. And when it shows nothing that changes anything, the honest answer is that the sensor was a description, and the main page said it might be.